The American College of Obstetrics and Gynecology now recommends that women be screened for depression during pregnancy. Because depressive symptoms during pregnancy have been associated with worse outcomes and are a robust predictor of postpartum [...]
Need a new search?
If you didn't find what you were looking for, try a new search!
June 1, 2002 from ObGynNews By Lee S. Cohen, M.D. Bipolar disorder is a chronic relapsing illness with a deteriorating course over time, particularly if there have been multiple episodes. This creates a bind for [...]
Because women with bipolar disorder are at high risk for relapse during the postpartum period, we typically recommend that women continue treatment with lithium throughout the postpartum period. While this intervention clearly decreases risk for postpartum psychiatric illness, the use of lithium while breastfeeding presents certain challenges.
For many women with bipolar disorder, lamotrigine (Lamictal) is an effective mood stabilizer. Given its relatively favorable reproductive safety profile, lamotrigine is a reasonable option for women who require treatment with a mood stabilizer during pregnancy.
This week in the New York Times, there is a two-part story on maternal mental illness. Highlighting the experience of two women who became ill during the postpartum period, the articles focus on the range of disorders which can emerge during the postpartum period -- not only depression, but bipolar disorder, anxiety, OCD, and psychosis.
Previous studies have identified primiparity as a significant risk factor for postpartum psychosis and especially bipolar affective disorders. This is the first study to quantify the risk of psychiatric illness after the first as compared to subsequent pregnancies.
Despite the use of the newer “atypical” antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, three is relatively little data on the reproductive safety of these newer atypical agents.
Since their introduction in the 1990s, atypical (second-generation) antipsychotics have replaced typical (first generation) antipsychotics as the first-line treatment for schizophrenia and related psychotic disorders. These drugs are widely used by reproductive age women across many other disease states including bipolar disorder, major depression and anxiety disorders as either primary or adjunctive treatments.
Atypical antipsychotic medications are commonly used for the treatment of schizophrenia and bipolar disorder. Despite the increasing use of these medications in women of child-bearing age, there is still relatively little data regarding the reproductive safety and long-term neurodevelopmental effects of these medications. A recent study assessed the development of 76 infants with fetal exposure to atypical antipsychotics.
Atypical antipsychotic medications are commonly used for the treatment of schizophrenia and bipolar disorder. Despite the increasing use of these medications in women of child-bearing age, there is still relatively little data regarding the reproductive safety of these medications.